Archives
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-08-12
This FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links restored nuclear p21 expression to cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression, while demonstrating bladder-focused delivery with limited transient systemic distribution in mice.
-
Azithromycin and Roxithromycin as Senolytics
2026-08-12
Ozsvari and colleagues identified azithromycin and roxithromycin as clinically approved macrolides that preferentially eliminate DNA-damage-induced senescent human fibroblasts. Their screening and validation strategy connects senolytic selectivity with altered glycolysis, autophagy, and mitochondrial respiration while also showing that closely related erythromycin lacks the same activity.
-
JNJ-26854165: Practical Cancer Assay Workflows
2026-08-11
Learn how to use JNJ-26854165 (Serdemetan) to connect HDM2 inhibition with proliferation arrest, apoptosis, migration, and radiation response. The workflow emphasizes time-resolved and orthogonal measurements so researchers can distinguish reduced growth from true cell killing.
-
FNPs for Stable Lung-Specific mRNA Delivery
2026-08-11
Cao and colleagues developed five-element nanoparticles that combine helper-polymer poly(β-amino esters) with DOTAP to improve lung-directed mRNA delivery and formulation stability. The study identified polymer features associated with stronger performance and reported that lyophilized formulations remained stable at 4 °C for at least six months, offering a practical framework for reducing cold-chain dependence.
-
EZ Cap™ Firefly Luciferase mRNA Workflow Guide
2026-08-10
Learn how to use EZ Cap™ Firefly Luciferase mRNA for quantitative delivery, translation, gene regulation, and imaging workflows. The guide combines practical handling instructions with a formulation-aware framework inspired by recent mRNA-LNP immunogenicity research.
-
Probenecid Workflows for Transporter Research
2026-08-09
Probenecid supports practical studies of MRP-mediated drug efflux, pannexin-1 activity, and neuroinflammatory injury. This workflow guide also shows how to use it cautiously as a transporter and membrane-signaling perturbation when studying CD8+ T-cell metabolic flexibility.
-
mCherry mRNA: From Signal to Translational Insight
2026-08-08
A thought-leadership guide to using Cap 1, modified-nucleotide mCherry mRNA as a reproducible reporter layer for biosensing, assay development, and translational decision-making.
-
EZ Cap™ Cy5 EGFP mRNA: Assay Design Guide
2026-08-07
Discover how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) can separate nanoparticle uptake from productive translation in advanced delivery studies. This guide connects dual-fluorescence reporter design with insights from hyaluronated lipid nanoparticle research and provides practical assay-planning recommendations.
-
Golgi-Tracker Green: Illuminating Organelle Stress and Sphin
2026-08-07
Explore how Golgi-Tracker Green, a BODIPY FL-labeled C5-ceramide probe, enables advanced live-cell Golgi apparatus labeling and reveals new insights into organelle stress and sphingolipid metabolism. This article uniquely bridges fundamental cell biology with translational oncology and assay optimization.
-
CRISPR Activation Enables Splice Variant Profiling in Fibrob
2026-08-06
Terkelsen et al. (2024) demonstrate that CRISPR activation can induce expression of tissue-restricted genes in skin fibroblasts, enabling functional characterization of splice-altering variants in a clinically accessible context. This approach addresses a longstanding barrier in rare disease diagnostics and expands the range of genes amenable to RNA-based analysis.
-
Canagliflozin Remodels Mitochondria in Diabetic Hypertensive
2026-08-06
This study reveals that canagliflozin, a selective SGLT2 inhibitor, improves both the structure and function of mitochondria in proximal tubular cells of hypertensive–diabetic mice. These mitochondrial changes may underpin the renal protective effects of SGLT2 inhibition, offering new mechanistic insight for diabetes and kidney disease research.
-
Amyloid β-Peptide (1-42): Mechanistic Leverage for Translati
2026-08-05
Explore how Amyloid β-Peptide (1-42) (Aβ42) is redefining Alzheimer’s disease (AD) research through mechanistic insight, assay innovation, and translational strategy. This article integrates foundational biology, state-of-the-art ratiometric imaging, and practical protocol guidance, uniquely bridging laboratory rigor with clinical ambition. Building on recent advances and APExBIO’s validated reagent, we chart a course for researchers seeking both robust neurotoxicity models and actionable data for therapeutic development.
-
Sex-Biased Gene Expression in Neural Differentiation of hESC
2026-08-05
This study provides the first genome-wide analysis of sex-biased gene expression during neural differentiation in multiple human embryonic stem cell lines, independent of hormonal effects. The findings reveal intrinsic genetic sex differences that influence neuronal development trajectories, with implications for understanding sex-specific neurodevelopmental disorders.
-
Eliminating Pollen Interference in EEM-Based Hazardous Subst
2026-08-04
Zhang et al. (2024) present a robust approach to mitigate pollen-induced spectral interference when classifying hazardous substances via excitation–emission matrix (EEM) fluorescence spectroscopy. By integrating advanced spectral preprocessing, machine learning, and feature transformation, their method significantly improves detection accuracy for bioaerosols—enabling more reliable environmental monitoring and public health protection.
-
EV-Transferred ACLY Promotes Immunosuppressive TAMs in HCC
2026-08-04
This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) loaded with ATP-citrate lyase (ACLY), which are taken up by monocytes to drive their differentiation into tumor-associated macrophages (TAMs) with immunosuppressive properties. The findings establish a mechanistic metabolic link between tumor cell-derived EVs, monocyte programming, and immune evasion in liver cancer, suggesting new therapeutic strategies targeting TAMs.